Best of ASCO - 2014 Annual Meeting



Attend this session at the
2018 ASCO Annual Meeting!

Session: Genitourinary (Prostate) Cancer

Type: Poster Session

Time: Saturday June 2, 1:15 PM to 4:45 PM

Location: Hall A

Expression of immune checkpoints (ICs) on circulating tumor cells (CTCs) in men with metastatic prostate cancer (mPC).


Genitourinary (Prostate) Cancer

2018 ASCO Annual Meeting

Abstract No:

Poster Board Number:
Poster Session (Board #286)

J Clin Oncol 36, 2018 (suppl; abstr 5059)

Author(s): Tian Zhang, Rebecca Garland Austin, Sally E Park, Daniella Runyambo, Rengasamy Boominathan, Chandra Rao, Elizabeth Bronson, Monika Anand, Patrick Healy, Daniel J. George, Megan Ann McNamara, Andrew J. Armstrong; Duke University Medical Center, Durham, NC; Emory University School of Medicine, Atlanta, GA; Albert Einstein College of Medicine, New York, NY; Duke Cancer Institute, Duke University, Durham, NC; Veridex LLC, Huntingdon Valley, PA; Duke University, Durham, NC; Duke University Medical Center, Mornsville, NC

Abstract Disclosures


Background: Most immune checkpoint inhibitors have shown limited efficacy in unselected men with mPC, and there is limited understanding about which ICs are relevant in mPC. We evaluated ICs on the cell surface of CTCs in patients (pts) with mPC. Methods: Pts were enrolled prospectively at the Duke Cancer Center in three cohorts: A) metastatic castration resistant prostate cancer (mCRPC) starting abiraterone acetate (AA) or enzalutamide (enza), B) mCRPC after AA or enza, and C) metastatic hormone sensitive PC (mHSPC). The Cellsearch platform was used to capture EpCAM- and CK-expressing CTCs and analyzed for PD-L1, PD-L2, B7-H3, and CTLA-4 expression at baseline, 12 weeks, and disease progression. Results: Through December 2017, we enrolled 18 pts (6 in cohort A, 8 in cohort B, and 4 in cohort C). CTCs were detectable in every cohort. At baseline, B7-H3 was the most prevalent IC while the other ICs were detected less frequently (Table 1). PD-L1 expression on CTCs was heterogeneous between and within pts; PD-L1 expression also changed during treatment and upon disease progression (Table 1). Rare CTCs expressed CTLA-4 and PD-L2, mostly in cohort B. Conclusions: Patients with mPC have detectable and heterogeneous ICs on CTCs, particularly PD-L1 and B7-H3, which can be monitored over time. B7-H3 was the most prevalent IC on CTCs, regardless of disease state. Our preliminary data suggest that pts with mCRPC post-enza/AA have higher levels of IC expression on CTCs compared with pts with mHSPC and mCRPC prior to enza/AA. We found evidence for heterogeneous CTC expression of CTLA-4 and PD-L2, particularly in men with mCRPC post-AA/enza.

Percentage of CTCs with immune checkpoint over total CTCs at baseline, week 12, and disease progression.

Median (range) of CTCs at baseline/week 12/PDPD-L1 (%) baseline/week 12/PDPD-L2 (%) baseline/week 12/PDCTLA-4 (%) baseline/week 12/PDB7-H3 (%) baseline/week 12/PD
A: mCRPC pre AA/enza16 (0-59)/6 (0-50)/31 (16-49)7/4/81/2/10/0/092/53/66
B: mCRPC post AA/enza4 (0-54)/1 (0-4)/3 (0-108)25/17/93/50/015/50/198/80/94
C: mHSPC3 (0-52)/0 (0-1)/NE11/100/NE6/NE/NE3/NE/NE68/NE/NE

NE: Not evaluable; PD: disease progression

Other Abstracts in this Sub-Category:


1. The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).

Meeting: 2018 ASCO Annual Meeting Abstract No: 5004 First Author: Andrew J. Armstrong
Category: Genitourinary (Prostate) Cancer - Biomarkers/Epidemiology/Outcomes


2. Six-month patient-reported outcome (PRO) results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate + prednisone (AAP) or enzalutamide (ENZ).

Meeting: 2018 ASCO Annual Meeting Abstract No: 5058 First Author: Antoine Thiery Vuillemin
Category: Genitourinary (Prostate) Cancer - Biomarkers/Epidemiology/Outcomes


3. The association of BRCA1 and BRCA2 mutations on prostate cancer risk, frequency, and mortality: Systematic review and meta-analysis.

Meeting: 2018 ASCO Annual Meeting Abstract No: 5060 First Author: Mok Oh
Category: Genitourinary (Prostate) Cancer - Biomarkers/Epidemiology/Outcomes